Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2024 Earnings Conference Call July 24, 2024 4:30 PM ET

Company Participants

Stephanie Diaz - Manager, IR
Brian Lian - President and CEO
Greg Zante - CFO

Conference Call Participants

Asim Rana - Truist Securities
Steve Seedhouse - Raymond James
Jay Olson - Oppenheimer
Annabel Samimy - Stifel
Roger Song - Jefferies
Andrew Hsieh - William Blair
Rohit Bhasin - Morgan Stanley
Justin Zelin - BTIG
Thomas Smith - Leerink Partners
Yale Jen - Laidlaw Company

Operator

Welcome to the Viking Therapeutics Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this conference call is being recorded today, July 24, 2024.

I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Stephanie Diaz

Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO, and Greg Zante, Viking's CFO.

Before we begin, I'd like to caution that comments made during this conference call today, July 24, 2024, will contain forward-looking statements under the Safe Harbor provisions of the U.S. Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, timelines, and milestones.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters.

I'll now turn the call over to Brian Lian for his initial comment.

Brian Lian

Thanks, Stephanie, and good afternoon to everyone listening in by phone, or on the webcast. Today we'll review our financial results for the second quarter and six months ended June 30, 2024, and provide an update on recent progress with our clinical programs and operations.

The first half of 2024 has been an exciting time at Viking. During the first quarter, we announced positive results from the Phase 2 VENTURE trial evaluating VK2735 for the treatment of obesity. This trial demonstrated impressive reductions in body weight after 13 weeks of treatment. We also announced the initial results from a Phase 1 trial evaluating a novel oral formulation of VK2735 in healthy volunteers, which showed encouraging reductions in body weight and excellent tolerability after 28 days of dosing.